| Literature DB >> 28168870 |
Valérie Hinard1, Aurore Britan1, Mathieu Schaeffer1, Monique Zahn-Zabal1, Urs Thomet2, Jean-Sébastien Rougier2, Amos Bairoch3, Hugues Abriel2, Pascale Gaudet1,3.
Abstract
Voltage-gated sodium channels are pore-forming transmembrane proteins that selectively allow sodium ions to flow across the plasma membrane according to the electro-chemical gradient thus mediating the rising phase of action potentials in excitable cells and playing key roles in physiological processes such as neurotransmission, skeletal muscle contraction, heart rhythm, and pain sensation. Genetic variations in the nine human genes encoding these channels are known to cause a large range of diseases affecting the nervous and cardiac systems. Understanding the molecular effect of genetic variations is critical for elucidating the pathologic mechanisms of known variations and in predicting the effect of newly discovered ones. To this end, we have created a Web-based tool, the Ion Channels Variants Portal, which compiles all variants characterized functionally in the human sodium channel genes. This portal describes 672 variants each associated with at least one molecular or clinical phenotypic impact, for a total of 4,658 observations extracted from 264 different research articles. These data were captured as structured annotations using standardized vocabularies and ontologies, such as the Gene Ontology and the Ion Channel ElectroPhysiology Ontology. All these data are available to the scientific community via neXtProt at https://www.nextprot.org/portals/navmut.Entities:
Keywords: clinical interpretation of variants; databases; genetics variants; pathogenicity; phenotype; voltage-gated sodium channel
Mesh:
Substances:
Year: 2017 PMID: 28168870 PMCID: PMC5413847 DOI: 10.1002/humu.23191
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878
Diseases associated with mutations in voltage‐gated sodium channels
| Gene | Protein | OMIM ID | neXtProt ID | Major Expression | Human Disorders due to Mutations in Voltage‐Gated Sodium Channels |
|---|---|---|---|---|---|
|
| Nav1.1 | 182389 | NX_P35498 | CNS, PNS | Generalized Epilepsy with Febrile Seizures Plus, Dravet Syndrome, Febrile Seizure, Familial Hemiplegic Migraine, Acute Encephalopathy, Juvenile Myoclonic Epilepsy Intractable without Status Epilepticus |
|
| Nav1.2 | 182390 | NX_Q99250 | CNS, PNS | Epileptic encephalopathy, Dravet Syndrome, Autism, Intellectual Disability, Generalized Epilepsy with Febrile Seizures Plus |
|
| Nav1.3 | 182391 | NX_Q9NY46 | CNS, PNS | Partial Epilepsy, Generalized Epilepsy with Febrile Seizures Plus |
|
| Nav1.4 | 603967 | NX_P35499 | Skeletal muscle | Hypokalemic Periodic Paralysis, Hyperkalemic Periodic Paralysis, Paramyotonia Congenita, Myotonic Disorder |
|
| Nav1.5 | 600163 | NX_Q14524 | Cardiac muscle | Brugada Syndrome, Long QT Syndrome, Ventricular Arrhythmia, Sudden Infant Death Syndrome, Dilated Cardiomyopathy, Sick Sinus Syndrome |
|
| Nav1.6 | 600702 | NX_Q9UQD0 | CNS, PNS | Epileptic encephalopathy, Migrating Partial Seizures in Infancy, Intellectual Disability |
|
| Nav1.7 | 603415 | NX_Q15858 | PNS | Primary Erythromelalgia, Pain Insensitivity, Paroxysmal Extreme Pain Disorder, Small Fiber Neuropathy |
|
| Nav1.8 | 604427 | NX_Q9Y5Y9 | PNS | Peripheral Neuropathy, Primary Erythromelalgia, Small Fiber Neuropathy |
|
| Nav1.9 | 604385 | NX_Q9UI33 | PNS | Small Fiber Neuropathy, Episodic Pain Syndrome Familial 3, Neuropathy Hereditary Sensory and Autonomic Type VII |
Note: CNS, central nervous system; PNS, peripheral nervous system.
Figure 1Topology of voltage‐gated sodium channels
Regions related to sodium channel's function
| Channel Function | Interaction Partners | Region |
|---|---|---|
|
| S1, S2, S3, and S4 | |
|
| S5‐S6 loop | |
|
| L3 | |
|
| S4‐S5 loop in DIII | |
|
| N‐term and C‐term | |
|
| ||
| PKC | L1 and L3 | |
| PKA | L1 | |
| CSNK2A2 | L2 | |
| GSK3B | C‐term | |
|
| ||
| Ankyrin | L2 | |
| Calmodulin | C‐term | |
| NEDD4L | C‐term | |
| FGF | C‐term |
Annotation elements: (A) basic triplet statement for “SCN5A‐p.Ser2014*” variant, (B) relations, and (C) evidence for the triplet “SCN5A‐p.Ser2014* decreases macroscopic conductance”
| A. ANNOTATION | ||
|---|---|---|
| Element | CV/Ontology | Example |
| Subject | HGVS nomenclature | SCN5A‐p.Ser2014* |
| Relation | cv_modification_effect.obo | Decreases |
| Object | BioObject/GO/ICEPO/ Protein Property/MGI phenotype | Binding to SNT (BioObject) cardiac conduction (GO) macroscopic conductance (ICEPO) protein abundance (Protein Property) |
Figure 2Screenshot of the Ion Channels Variants Portal. Each column can be filtered for specific values and sorted alphabetically or numerically, depending on the data type. The number of entries corresponding to a search result appears above the table
Number of variants and annotations in the Ion Channels Variants Portal per channel and number of disease‐associated variants obtained from the ClinVar and neXtProt databases. The last row presents the proportion of naturally occurring variants from our set of variants for each channel
| SCN1A | SCN2A | SCN3A | SCN4A | SCN5A | SCN8A | SCN9A | SCN10A | SCN11A | Total | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 535 | 860 | 51 | 1,294 | 1,063 | 163 | 514 | 119 | 59 |
|
|
| 51 | 184 | 7 | 200 | 112 | 27 | 59 | 27 | 5 |
|
|
| 506 | 50 | 6 | 72 | 529 | 26 | 62 | 27 | 11 |
|
|
|
|
|
|
|
|
|
|
|
|
Figure 3Distribution of the variants according to the topological domains: A: DI–DIV domains versus cytoplasmic regions. Distribution of the variants with electrophysiological defects: the natural variants (Nat_Var) versus artificial variants (Artif_Var) according to (B) the domains or to (C) the segments
Number of natural (Nat_var) or artificial variants (Artif_var) present in DI–DIV domains or cytoplasmic regions (cyto)
| SCN1A | SCN2A | SCN3A | SCN4A | SCN5A | SCN8A | SCN9A | SCN10A | SCN11A | Total | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 43 | 17 | 6 | 30 | 47 | 5 | 33 | 5 | 5 |
|
|
| 6 | 6 | 0 | 10 | 45 | 1 | 11 | 2 | 0 |
|
|
| 2 | 137 | 0 | 130 | 7 | 8 | 8 | 12 | 0 |
|
|
| 0 | 24 | 1 | 30 | 13 | 13 | 7 | 8 | 0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Figure 4Stacked fraction of (A) the disease‐causing variants per region and of (B) the characterized variants per region